Leerink Partnrs Has Strong Estimate for Icon FY2025 Earnings

Icon Plc (NASDAQ:ICLR) – Analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of Icon in a research report issued to clients and investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $12.68 per share for the year, up from their prior estimate of $12.66. The consensus estimate for Icon’s current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for Icon’s FY2026 earnings at $13.54 EPS and FY2027 earnings at $15.41 EPS.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, April 30th. The medical research company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.17 by $0.02. Icon had a net margin of 9.25% and a return on equity of 11.46%. The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter in the previous year, the firm posted $3.47 EPS. Icon’s revenue was down 4.3% on a year-over-year basis.

Several other research analysts have also recently weighed in on ICLR. Robert W. Baird decreased their price target on shares of Icon from $192.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. JPMorgan Chase & Co. cut Icon from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $265.00 to $150.00 in a research note on Tuesday, April 29th. Mizuho reduced their target price on Icon from $200.00 to $173.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. TD Cowen cut Icon from a “buy” rating to a “hold” rating and reduced their target price for the company from $254.00 to $157.00 in a research note on Monday, April 14th. Finally, Citigroup cut their price target on shares of Icon from $290.00 to $215.00 and set a “buy” rating for the company in a research report on Monday, April 7th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Icon presently has a consensus rating of “Moderate Buy” and a consensus price target of $198.08.

Icon Trading Down 1.0%

Icon stock opened at $150.52 on Friday. The stock has a market cap of $12.16 billion, a P/E ratio of 16.40, a PEG ratio of 1.86 and a beta of 1.17. Icon has a fifty-two week low of $125.10 and a fifty-two week high of $347.72. The firm’s fifty day moving average price is $140.25 and its 200-day moving average price is $167.99. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.27 and a current ratio of 1.27.

Institutional Investors Weigh In On Icon

Institutional investors and hedge funds have recently made changes to their positions in the company. UMB Bank n.a. boosted its stake in shares of Icon by 57.7% during the 2nd quarter. UMB Bank n.a. now owns 2,146 shares of the medical research company’s stock worth $312,000 after acquiring an additional 785 shares during the last quarter. Diversified Trust Co boosted its stake in shares of Icon by 6.2% during the 2nd quarter. Diversified Trust Co now owns 3,059 shares of the medical research company’s stock worth $445,000 after acquiring an additional 179 shares during the last quarter. Canoe Financial LP boosted its stake in shares of Icon by 10.3% during the 2nd quarter. Canoe Financial LP now owns 193,851 shares of the medical research company’s stock worth $28,196,000 after acquiring an additional 18,174 shares during the last quarter. Western Pacific Wealth Management LP purchased a new position in shares of Icon during the 2nd quarter valued at $201,000. Finally, Bruce G. Allen Investments LLC lifted its stake in shares of Icon by 1,772.7% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 412 shares of the medical research company’s stock valued at $60,000 after buying an additional 390 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.